MKI67 and neoplasm: Evaluation of Ki67-positive cells in the tumor samples, demonstrated a significant 48% decrease in proliferating cells after treatment with palbociclib, while the combination therapy reduced the number of Ki67-positive cells by 24% compared to vehicle treatment (Figure 7D).